The Degenerative Disc Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Degenerative Disc Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Degenerative Disc Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Degenerative Disc Disease by 14 companies/universities/institutes. The top development phase for Degenerative Disc Disease is preclinical with seven drugs in that stage. The Degenerative Disc Disease pipeline has 17 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Degenerative Disc Disease pipeline products market are: DiscGenics, Kolon TissueGene and Astellas Pharma.
The key targets in the Degenerative Disc Disease pipeline products market include Serine/Threonine Protein Kinase Nek7, Nuclear Factor Kappa B, and TGF Beta Receptor Type 1.
The key mechanisms of action in the Degenerative Disc Disease pipeline product include Nuclear Factor Kappa B Inhibitor with one drug in Phase I. The Degenerative Disc Disease pipeline products include five routes of administration with the top ROA being Parenteral and seven key molecule types in the Degenerative Disc Disease pipeline products market including Cell Therapy, and Small Molecule.
Degenerative Disc Disease overview
Degenerative disc disease is refers to degeneration of the intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, pain relievers, and antidepressants.
For a complete picture of Degenerative Disc Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
